Bio-Rad Laboratories Inc. - Ordinary Shares - Class A

NYSE:BIO  
721.71
+1.60 (+0.22%)
4:00:00 PM EDT: $721.06 -0.65 (-0.09%)
Other Pre-Announcement

Bio Rad Laboratories Sees FY Sales $2.75 Billion To $2.85 Billion

Published: 12/10/2020 22:48 GMT
Bio-Rad Laboratories Inc. - Ordinary Shares - Class A (BIO) - Sees FY Sales $2.75 Billion to $2.85 Billion.
Expects Fiscal Year 2023 Sales to Be Between $2.75 Billion and $2.85 Billion.
Bio Rad Laboratories - for Fiscal Year 2023, Expects to Achieve Non-GAAP Adjusted EBITDA Margin of 23 to 24%.